The role of Goldilocks protein kinase DYRK1A in embryonic development
H Katherine Johnson1, Larisa L Litovchick2, Amanda J G Dickinson1
1Department of Biology, Virginia Commonwealth University, Richmond, VA, USA.
Abstract:
DYRK1A (Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) is a dosage-sensitive gene whose expression must be tightly regulated to support normal development. This is supported by studies in animal models which demonstrate that both insufficient and excessive DYRK1A/Dyrk1a activity can impair development across multiple organ systems. In humans, both gain and loss-of-function alterations can disrupt the levels of DYRK1A, leading to structural birth defects and neurodevelopmental disorders. For example, DYRK1A haploinsufficiency causes DYRK1A syndrome, marked by intellectual disability and characteristic craniofacial features. DYRK1A is located on chromosome 21, and its overexpression in the context of trisomy 21 is believed to contribute to the developmental anomalies and comorbidities seen in Down syndrome. Notably, normalizing DYRK1A genetically or pharmacologically in Down syndrome mouse models can partially rescue phenotypes, underscoring its pathogenic role in this genetic condition. This review highlights the critical need to understand the effects of altering DYRK1A dosage during embryogenesis to inform therapeutic strategies for DYRK1A related disorders and Down syndrome associated birth defects.
Insights
Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A (DYRK1A) dosage is critical for development. Altering DYRK1A levels causes birth defects and neurodevelopmental disorders, including Down syndrome, highlighting its pathogenic role.
Area of Science:
- Developmental Biology
- Genetics
- Molecular Biology
Background:
- DYRK1A (Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 1A) is a dosage-sensitive gene crucial for normal development.
- Both insufficient and excessive DYRK1A activity impair development across organ systems, as shown in animal models.
- Human genetic alterations in DYRK1A lead to structural birth defects and neurodevelopmental disorders.
Purpose of the Study:
- To review the critical role of DYRK1A dosage during embryogenesis.
- To highlight the pathogenic contribution of DYRK1A in Down syndrome and related disorders.
- To inform therapeutic strategies for DYRK1A-related conditions.
Main Methods:
- Review of existing literature on DYRK1A function and its role in developmental disorders.
- Analysis of animal model studies demonstrating the impact of altered Dyrk1a activity.
- Examination of human genetic data linking DYRK1A alterations to specific syndromes.
Main Results:
- DYRK1A haploinsufficiency causes DYRK1A syndrome, characterized by intellectual disability and craniofacial abnormalities.
- Overexpression of DYRK1A in trisomy 21 contributes to developmental anomalies in Down syndrome.
- Genetic or pharmacological normalization of DYRK1A in Down syndrome models partially rescues phenotypes.
Conclusions:
- DYRK1A dosage is essential for normal embryonic development.
- DYRK1A plays a significant pathogenic role in Down syndrome and other genetic disorders.
- Understanding DYRK1A's developmental effects is key for developing targeted therapies.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
02:15M-Cdk Drives Transition Into Mitosis
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
01:07MAPK Signaling Cascades
02:34Inhibition of Cdk Activity
02:39Positive Regulator Molecules
01:23Negative Regulator Molecules